N W D Lamond1, C Skedgel2, D Rayson3, T Younis3. 1. Department of Medicine, Dalhousie University, Halifax, NS; 2. Atlantic Clinical Cancer Research Unit, QEII Health Sciences Centre, Halifax, NS. 3. Department of Medicine, Dalhousie University, Halifax, NS; ; Atlantic Clinical Cancer Research Unit, QEII Health Sciences Centre, Halifax, NS.
Abstract
BACKGROUND: Adjuvant zoledronic acid (za) appears to improve disease-free survival (dfs) in women with early-stage breast cancer and low levels of estrogen (lle) because of induced or natural menopause. Characterizing the cost-utility (cu) of this therapy could help to determine its role in clinical practice. METHODS: Using the perspective of the Canadian health care system, we examined the cu of adjuvant endocrine therapy with or without za in women with early-stage endocrine-sensitive breast cancer and lle. A Markov model was used to compute the cumulative costs in Canadian dollars and the quality-adjusted life-years (qalys) gained from each adjuvant strategy, discounted at a rate of 5% annually. The model incorporated the dfs and fracture benefits of adjuvant za. Probabilistic and one-way sensitivity analyses were conducted to examine key model parameters. RESULTS: Compared with a no-za strategy, adjuvant za in the induced and natural menopause groups was associated with, respectively, $7,825 and $7,789 in incremental costs and 0.46 and 0.34 in qaly gains for cu ratios of $17,007 and $23,093 per qaly gained. In one-way sensitivity analyses, the results were most sensitive to changes in the za dfs benefit. Probabilistic sensitivity analysis suggested a 100% probability of adjuvant za being a cost-effective strategy at a threshold of $100,000 per qaly gained. CONCLUSIONS: Based on available data, adjuvant za appears to be a cost-effective strategy in women with endocrine-sensitive breast cancer and lle, having cu ratios well below accepted thresholds.
BACKGROUND: Adjuvant zoledronic acid (za) appears to improve disease-free survival (dfs) in women with early-stage breast cancer and low levels of estrogen (lle) because of induced or natural menopause. Characterizing the cost-utility (cu) of this therapy could help to determine its role in clinical practice. METHODS: Using the perspective of the Canadian health care system, we examined the cu of adjuvant endocrine therapy with or without za in women with early-stage endocrine-sensitive breast cancer and lle. A Markov model was used to compute the cumulative costs in Canadian dollars and the quality-adjusted life-years (qalys) gained from each adjuvant strategy, discounted at a rate of 5% annually. The model incorporated the dfs and fracture benefits of adjuvant za. Probabilistic and one-way sensitivity analyses were conducted to examine key model parameters. RESULTS: Compared with a no-za strategy, adjuvant za in the induced and natural menopause groups was associated with, respectively, $7,825 and $7,789 in incremental costs and 0.46 and 0.34 in qaly gains for cu ratios of $17,007 and $23,093 per qaly gained. In one-way sensitivity analyses, the results were most sensitive to changes in the za dfs benefit. Probabilistic sensitivity analysis suggested a 100% probability of adjuvant za being a cost-effective strategy at a threshold of $100,000 per qaly gained. CONCLUSIONS: Based on available data, adjuvant za appears to be a cost-effective strategy in women with endocrine-sensitive breast cancer and lle, having cu ratios well below accepted thresholds.
Entities:
Keywords:
Adjuvant therapy; bone health; breast cancer; cost–utility; economic analyses; zoledronic acid
Authors: Adam M Brufsky; W Graydon Harker; J Thaddeus Beck; Linda Bosserman; Charles Vogel; Christopher Seidler; Lixian Jin; Ghulam Warsi; Eliza Argonza-Aviles; John Hohneker; Solveig G Ericson; Edith A Perez Journal: Cancer Date: 2011-10-10 Impact factor: 6.860
Authors: P Hadji; M S Aapro; J J Body; N J Bundred; A Brufsky; R E Coleman; M Gnant; T Guise; A Lipton Journal: Ann Oncol Date: 2011-03-17 Impact factor: 32.976
Authors: Ticiana Leal; Amyé Tevaarwerk; Richard Love; James Stewart; Neil Binkley; Jens Eickhoff; Benjamin Parrot; Daniel Mulkerin Journal: Clin Breast Cancer Date: 2010-12-01 Impact factor: 3.225
Authors: R Coleman; R de Boer; H Eidtmann; A Llombart; N Davidson; P Neven; G von Minckwitz; H P Sleeboom; J Forbes; C Barrios; A Frassoldati; I Campbell; O Paija; N Martin; A Modi; N Bundred Journal: Ann Oncol Date: 2012-10-09 Impact factor: 32.976
Authors: Robert E Coleman; Helen Marshall; David Cameron; David Dodwell; Roger Burkinshaw; Maccon Keane; Miguel Gil; Stephen J Houston; Robert J Grieve; Peter J Barrett-Lee; Diana Ritchie; Julia Pugh; Claire Gaunt; Una Rea; Jennifer Peterson; Claire Davies; Victoria Hiley; Walter Gregory; Richard Bell Journal: N Engl J Med Date: 2011-09-25 Impact factor: 91.245
Authors: F Saad; J E Brown; C Van Poznak; T Ibrahim; S M Stemmer; A T Stopeck; I J Diel; S Takahashi; N Shore; D H Henry; C H Barrios; T Facon; F Senecal; K Fizazi; L Zhou; A Daniels; P Carrière; R Dansey Journal: Ann Oncol Date: 2011-10-10 Impact factor: 32.976